TY - JOUR
T1 - Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis
AU - Masarova, Lucia
AU - Alhuraiji, Ahmad
AU - Bose, Prithviraj
AU - Daver, Naval
AU - Pemmaraju, Naveen
AU - Cortes, Jorge
AU - Pierce, Sherry
AU - Kantarjian, Hagop
AU - Verstovsek, Srdan
N1 - Funding Information:
This work was supported in part by the MD Anderson Cancer Center Support Grant CA016672 from the National Cancer Institute (National Institutes of Health).
Publisher Copyright:
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
PY - 2018/3
Y1 - 2018/3
N2 - Severe thrombocytopenia (platelets <50 × 109/L) is associated with very poor outcome of patients with myelofibrosis (MF). As patients with primary myelofibrosis (PMF) differ from patients with postessential thrombocythemia (PET-MF) and postpolycythemia vera myelofibrosis (PPV-MF), we aimed to evaluate the significance of low platelets among these patients. We present clinical characteristics and outcome of patients with either PMF, PPV-MF, or PET-MF, and thrombocytopenia who presented to our institution between 1984 and 2015. Of 1269 patients (877 PMF, 212 PPV-MF, 180 PET-MF), 11% and 14% had platelets either <50 × 109/L or between 50-100 × 109/L, respectively. Patients with platelets <50 × 109/L were most anemic and transfusion dependent, had highest blast count and unfavorable karyotype. In general, their overall and leukemia-free survival was the shortest with median time of 15 and 13 months, respectively; with incidence of acute leukemia almost twice as high as in the remaining patients (6.9 vs 3.6 cases per 100 person-years). Nevertheless, this observation remains mostly significant for patients with PMF, as those with PEV/PVT-MF have already significantly inferior prognosis with platelets <100 × 109/L.
AB - Severe thrombocytopenia (platelets <50 × 109/L) is associated with very poor outcome of patients with myelofibrosis (MF). As patients with primary myelofibrosis (PMF) differ from patients with postessential thrombocythemia (PET-MF) and postpolycythemia vera myelofibrosis (PPV-MF), we aimed to evaluate the significance of low platelets among these patients. We present clinical characteristics and outcome of patients with either PMF, PPV-MF, or PET-MF, and thrombocytopenia who presented to our institution between 1984 and 2015. Of 1269 patients (877 PMF, 212 PPV-MF, 180 PET-MF), 11% and 14% had platelets either <50 × 109/L or between 50-100 × 109/L, respectively. Patients with platelets <50 × 109/L were most anemic and transfusion dependent, had highest blast count and unfavorable karyotype. In general, their overall and leukemia-free survival was the shortest with median time of 15 and 13 months, respectively; with incidence of acute leukemia almost twice as high as in the remaining patients (6.9 vs 3.6 cases per 100 person-years). Nevertheless, this observation remains mostly significant for patients with PMF, as those with PEV/PVT-MF have already significantly inferior prognosis with platelets <100 × 109/L.
KW - outcome
KW - postessential thrombocythemia myelofibrosis
KW - postpolycythemia vera myelofibrosis
KW - primary myelofibrosis
KW - thrombocytopenia
UR - http://www.scopus.com/inward/record.url?scp=85042093703&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042093703&partnerID=8YFLogxK
U2 - 10.1111/ejh.13005
DO - 10.1111/ejh.13005
M3 - Article
C2 - 29226426
AN - SCOPUS:85042093703
SN - 0902-4441
VL - 100
SP - 257
EP - 263
JO - European Journal of Haematology
JF - European Journal of Haematology
IS - 3
ER -